Evidence map›Paper›PMID 33291418›Full record

ArticleAntibiotics (Basel, Switzerland)2020

Antimicrobial Action and Reversal of Resistance in MRSA by Difluorobenzamide Derivatives Targeted at FtsZ.

Wern Chern Chai, Jonathan J Whittall, Di Song, Steven W Polyak, Abiodun D Ogunniyi, Yinhu Wang, Fangchao Bi, Shutao Ma, Susan J Semple, Henrietta Venter

Open access · goldAbstract read
In one paragraph

Article in Antibiotics (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.3field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Wern Chern ChaiHealth and Biomedical Innovation, Clinical and Health Sciences, University of South Australia, Adelaide 5000, South Australia, Australia.
Jonathan J WhittallHealth and Biomedical Innovation, Clinical and Health Sciences, University of South Australia, Adelaide 5000, South Australia, Australia.
Di SongDepartment of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education),School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan 250012, China.
Steven W PolyakHealth and Biomedical Innovation, Clinical and Health Sciences, University of South Australia, Adelaide 5000, South Australia, Australia.
Abiodun D OgunniyiAustralia Centre for Antimicrobial Resistance Ecology, School of Animal and Veterinary Sciences, University of Adelaide, Roseworthy Campus, 5371 Roseworthy, Australia.
Yinhu WangDepartment of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education),School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan 250012, China.
Fangchao BiDepartment of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education),School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan 250012, China.
Shutao MaDepartment of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education),School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan 250012, China.
Susan J SempleHealth and Biomedical Innovation, Clinical and Health Sciences, University of South Australia, Adelaide 5000, South Australia, Australia.
Henrietta VenterHealth and Biomedical Innovation, Clinical and Health Sciences, University of South Australia, Adelaide 5000, South Australia, Australia.
University of South Australia · AUShandong University · CNThe University of Adelaide · AU

Funding

National Health and Medical Research Council GN1147538National Natural Science Foundation of China 81673284)National Natural Science Foundation of China 81973179
6 · The paper itself

Abstract

The bacterial cell division protein, FtsZ, has been identified as a target for antimicrobial development. Derivatives of 3-methoxybenzamide have shown promising activities as FtsZ inhibitors in Gram-positive bacteria. We sought to characterise the activity of five difluorobenzamide derivatives with non-heterocyclic substituents attached through the 3-oxygen. These compounds exhibited antimicrobial activity against methicillin resistant

Indexed as

3-methoxybenzamideantimicrobial developmentantimicrobial resistanceFtsZ inhibitorsmethicillin resistant Staphylococcus aureusreversing resistance

Identifiers

PMID33291418
PMCPMC7762090
OpenAlexW3112777519

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.